Johnson & Johnson has announced a major expansion of its U.S. manufacturing capabilities with a $2 billion, 10-year investment in a new 160,000+ square foot facility at FUJIFILM’s state-of-the-art biopharmaceutical manufacturing site in Holly Springs, North Carolina. The project is expected to create approximately 120 new jobs in the region and further strengthen the company’s domestic production capacity for advanced medicines.
The new facility is part of a broader strategic push by Johnson & Johnson to manufacture the majority of its cutting-edge therapies within the U.S. to better meet the needs of American patients. The company also signaled that more U.S. facility announcements are on the horizon, including both new advanced manufacturing sites and expansions of existing ones.
“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and CEO of Johnson & Johnson. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”
This latest investment is part of the company’s broader $55 billion commitment—announced earlier this year—to bolster U.S.-based manufacturing, research and development, and technology over the next four years.
Construction is also progressing at Johnson & Johnson’s separate manufacturing site in Wilson, North Carolina, which is expected to employ over 500 people once operational and create around 5,000 construction jobs during development. These initiatives underscore the company’s emphasis on building local capacity to support innovation in key therapeutic areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.
By partnering with FUJIFILM and investing heavily in U.S. infrastructure, Johnson & Johnson is positioning itself to remain at the forefront of biopharmaceutical manufacturing while contributing significantly to local economies and job growth.